Nanobiotix (NBTX) Equity Average (2021 - 2025)
Nanobiotix has reported Equity Average over the past 5 years, most recently at -$88.2 million for Q4 2025.
- For Q4 2025, Equity Average fell 88.33% year-over-year to -$88.2 million; the TTM value through Dec 2025 reached -$88.2 million, down 88.33%, while the annual FY2025 figure was -$84.3 million, 133.47% down from the prior year.
- Equity Average for Q4 2025 was -$88.2 million at Nanobiotix, down from -$74.1 million in the prior quarter.
- Over five years, Equity Average peaked at $67.0 million in Q2 2021 and troughed at -$88.2 million in Q4 2025.
- A 5-year average of -$18.5 million and a median of -$21.6 million in 2022 define the central range for Equity Average.
- Biggest five-year swings in Equity Average: surged 70.48% in 2024 and later tumbled 482.92% in 2025.
- Year by year, Equity Average stood at $40.3 million in 2021, then crashed by 131.88% to -$12.8 million in 2022, then crashed by 135.78% to -$30.3 million in 2023, then tumbled by 54.69% to -$46.8 million in 2024, then plummeted by 88.33% to -$88.2 million in 2025.
- Business Quant data shows Equity Average for NBTX at -$88.2 million in Q4 2025, -$74.1 million in Q2 2025, and -$46.8 million in Q4 2024.